Compared with treatment with IL-2(PEG) or budesonide alone, intratracheal treatment with a combination of 5,000 IU IL-2(PEG):1 μg budesonide markedly reduced AHR of asthma model mice (Fig. 3c). This evidence concerns the gene IL2 and asthma.